— Data support the potential to explore lead Phase 1 monotherapy asset FX-909 in combination with an anti-PD1 agent — CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ — Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.